Cell death and life in cancer: mathematical modeling of cell fate
  decisions by Zinovyev, Andrei et al.
ar
X
iv
:1
30
1.
23
66
v1
  [
q-
bio
.M
N]
  1
1 J
an
 20
13
Cell death and life in cancer: mathematical
modeling of cell fate decisions
Andrei Zinovyev, Simon Fourquet, Laurent Tournier, Laurence Calzone and
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Abstract Tumor development is characterized by a compromised balance between
cell life and death decision mechanisms, which are tighly regulated in normal cells.
Understanding this process provides insights for developing new treatments for
fighting with cancer. We present a study of a mathematical model describing cel-
lular choice between survival and two alternative cell death modalities: apoptosis
and necrosis. The model is implemented in discrete modeling formalism and allows
to predict probabilities of having a particular cellular phenotype in response to en-
gagement of cell death receptors. Using an original parameter sensitivity analysis
developed for discrete dynamic systems, we determine variables that appear to be
critical in the cellular fate decision and discuss how they are exploited by existing
cancer therapies.
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1 Introduction
Evading various programmed cell death modalities is considered as one of the major
hallmarks of cancer cells [1]. A better understanding of the pro-death or prosurvival
roles of the genes associated with various cancers, and their interactions with other
pathways would set a ground for re-establishing a lost death phenotype and identi-
fying potential drug targets.
Recent progress in studying the mechanisms of cell life/death decisions revealed
its astounding complexity. Among many, one can mention three difficulties on the
way to characterize, describe and create strict mathematical descriptions of these
mechanisms.
First, the signaling network allowing a cell to react to an external stress (such as
damage of DNA, nutrient and oxygen deprivation, toxic environment) is assembled
from highly redundant pathways which are able to compensate each other in one
way or another. For example, there exist at least seven distinct and parallel survival
pathways associated with action of AKT protein [2]. Disruption of one of these
pathways in a potential cell death-inducing cancer therapy can be in principle com-
pensated by the others. Thus, understanding and modeling the survival response in
its full complexity is a daunting task.
Second, cellular death is an extremely complex phenotype that cannot merely
be described as a simple disaggregation of cellular components driven by purely
thermodynamical laws. Several distinct modes of cell death were identified in the
last decade [3], such as necrosis, apoptosis and autophagy. Importantly, all these cell
death modalities are controlled by cellular biochemical mechanisms, activated in re-
sponse to diverse types of stress: roughly speaking, a cell is usually pre-programmed
to die in a certain manner, sending appropriate signals to its surroundings so as to
limit tissue toxicity and allow recycling of its components. Necrosis is a type of
cell death usually associated with a lack of important cellular resource such as ATP,
which makes functioning of many biochemical pathways impossible. This is why it
was long thought of as an uncontrolled and purely thermodynamics-driven degra-
dation of cellular structures. However, recent research showed that necrosis can be
triggered by specific signals through the activation of tightly regulated pathways,
and can even proceed without ATP depletion [3]. By contrast, apoptosis as a form
of cellular suicide was, from the very beginning, described as a mode of cell death
requiring energy for the permeabilization of mitochondrial membranes and cleav-
age of intracellular structures. Autophagy remains a relatively poorly understood
cell death mechanism, which seems to serve both as a survival or a death modal-
ity. Upon certain stress conditions, and until this stress is relieved, cellular compo-
nents such as damaged proteins or organelles are digested and recycled into reusable
metabolites, and metabolism is reoriented so as to spare vital functions. Long last-
ing, non-relievable stress was described as triggering autophagic cell death, through
unaffordable cellular self-digestion. However, no experimental evidence ever un-
ambiguously demonstrated that such cell death is directly executed by autophagy in
vivo, but in the special case of the involution of Drosophila melanogaster salivary
glands [3].
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The third difficulty can be attributed not directly to the complexity of the bio-
chemical mechanisms but rather to our capabilities of apprehending the design prin-
ciples used by biological evolution. Inspired by engineering practices, we tend to
investigate complex systems by splitting them into relatively independent modules
and associating well-characterized non-overlapping functions to each molecular de-
tail. Applying such reductionist approaches to biology comes with a caveat. Most
cellular molecular machineries cannot be naturally dissected or associated with
well-defined functions, and sets of overlapping functions can be distributed among
groups of molecular players.
Not having the ambition to deal with the whole complexity of cell fate deci-
sions in vivo, we decided to concentrate on modeling the outcome of a classical and
rather well-defined experiment of inducing cell death: adding to a cell culture spe-
cific ligands (Tumor Necrosis Factor, TNF, or other members of its family such as
FASL). These so-called death ligands can engage death receptors and trigger apop-
tosis or necrosis, or activate pro-survival mechanisms [5]. The net outcome of such
experiments depends on many circumstances: cell type, dose of the ligand, duration
of the treatment, specific mutations in cell genomes, etc. Moreover, it is believed
that the outcome can have intrinsic stochastic nature governed by cellular decision
making mechanisms and intrinsic molecular noise [6]. Trying to characterize the
biochemical response of a cell to this relatively simple kind of perturbation allows
to understand certain cell fate decision mechanisms.
In this paper, we briefly describe and carefully analyze a mathematical model of
cell fate decision between survival and two alternative modes of cell death: apoptosis
and necrosis. The model was created and introduced in [4]. Here propose the prin-
ciples for wiring and parametrizing a biological diagram that describes this cellular
switch. In addition to [4], here, by applying a novel sensitivity analysis specifically
developed for discrete modeling, we identify fragile sites of the cell fate decision
mechanism. In conclusion, we compare our analysis with our current knowledge of
cellular decision making fragilities utilized by cancer and cancer therapies.
2 Mathematical model of cell fate decision
In [4] we summarized the current knowledge on the interactions between cell fate
decision mechanisms in a simplistic wiring diagram (see Fig. 1) where a node rep-
resents either a protein (TNF, FADD, FASL, TNFR, CASP8, cFLIP, BCL2, BAX,
IKK, NFκB, CYT C, SMAC, XIAP, CASP3), a state of protein (RIP1ub, RIP1K), a
small molecule (ROS, ATP), a molecular complex (Apoptosome, C2 TNF, DISC FAS),
a group of molecular entities sharing the same function (BAX can thus represent ei-
ther of BAX and BAK, cIAP either cIAP1 or cIAP2, and BCL2 any of the BH1-4
BCL2 family members,), a molecular process (Mitochondria permeabilization tran-
sition, MPT, Mitochondrial outer membrane permeabilization, MOMP) or a pheno-
type (Survival, Apoptosis, Non-apoptotic cell death, NonACD). Each directed and
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signed edge represents an influence of one molecular entity on another, either posi-
tive (arrowed edge) or negative (headed edge).
The phenotype nodes on the diagram are simple interpretations of the following
molecular conditions: 1) activated NFκB is read as survival state; 2) lack of ATP
is read as nonapoptotic cell death state; 3) activated CASP3 is read as apoptotic
cell death. Absence of any of such conditions is interpreted as a ”naive“ cell state,
corresponding to the fourth cellular phenotype.
After extensive examination of the biological literature we converted the diagram
into a logical mathematical model of cell fate decisions triggered by activation of
cell death receptors. The wiring diagram and the logical rules defining the model
are shown on Fig. 1.
By applying a technique adapted to discrete formalism [7], we reduced this model
to a 11-dimensional network, thus enabling a complete analysis of the asynchronous
dynamics (see [4] for details). This analysis identified 27 stable logical states and no
cyclic attractors. Moreover, it showed that the distribution of the stable logical states
in the discrete 22-dimensional space of internal model variables (without consider-
ing input and output variables) forms four compact clusters, each corresponding to a
particular cellular phenotype. Three of these clusters can be attributed to a particular
cell fate (survival, apoptosis, necrosis) while the forth represents a “naive” survival
state, where no death receptors are induced.
3 Computing phenotype probabilities
As we have already mentioned, the cellular fate decision machinery is characterized
by stochastic response, i.e. given a stimuli, the cell can reach several final states, cor-
responding to different phenotypes, with different probabilities. The role of mathe-
matical modeling in this case can be to predict these probabilities as absolute values
that can be matched to an experiment, or at least to predict the relative changes of
the probabilities after introducing some perturbations to the system.
We have implemented this idea for the mathematical model of cell fate decisions
described above in the following manner.
In order to describe our results, let us introduce the notion of asynchronous state
transition graph. On this graph, each node represents a state of the system which
in this case can be encoded by a n-dimensional vector of 0s and 1s (n being the
dimension of the system). A directed edge exists between two states x and y if there
exists an index i ∈ {1, . . . ,n} such that yi = fi(x) 6= xi and y j = x j for j 6= i (here, fi
denotes the logical rule of variable xi, see Fig. 1 for a complete list of the model logi-
cal rules). In principle, the state transition graph could be defined independently and
without the biological diagram, however, this would require a tremendous amount
of empirical knowledge about the set of all permissible transitions between the cell
states which is not available. Hence, the biological diagram with associated logical
rules is used as a compact representation and a tool to generate the state transition
graph. Detailed instructions on this procedure can be found in [8, 9].
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CASP3
SMAC
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BCL2
cFLIPRIP1K
cIAP
RIP1ub
IKK
NFkB
XIAP
ATP
RIP1
ApoptosisNonACDSurvival
DISC TNF’ = TNFR AND FADD TNF’ = TNF
RIP1’ = (TNFR OR DISC FAS) AND (NOT CASP8) FADD’ = FADD
CASP8’ = (DISC TNF OR DISC FAS OR CASP3) AND (NOT cFlip) FAS’ = FAS
RIPub’ = RIP1 AND cIAP TNFR’ = TNF
cIAP’ = (NFkB OR cIAP) AND (NOT SMAC) RIP1K’ = RIP1
BAX’ = CASP8 AND (NOT BCL2) cFlip’ = NFkB
ROS’ = (RIP1K OR MPT) AND (NOT NFkB) IKK’ = RIP1ub
MPT’ = ROS AND (NOT BCL2) BCL2’ = NFkB
MOMP’ = BAX OR MPT SMAC’ = MOMP
NFkB’ = IKK AND (NOT CASP3) CYT C’ = MOMP
XIAP’ = NFkB AND (NOT SMAC) DISC FAS’ = FAS AND FADD
Apoptosome’ = CYT C AND ATP AND (NOT XIAP) ATP’ = NOT MPT
CASP3’ = Apoptosome AND (NOT XIAP)
Fig. 1 Biological diagram of molecular interactions involved in cell fate decisions derived from
the biological literature. The diagram is roughly divided by dashed lines into three modules cor-
responding to three submechanisms of cell fate decisions. Notations: 1) Proteins: TNF, FADD,
FASL, TNFR, CASP8, cIAP, cFLIP, BCL2, BAX, IKK, NFκB, CYT C, SMAC, XIAP, CASP3;
2) States of proteins: RIP1ub (ubiquitinated form of RIP1), RIP1K (kinase function of RIP1); 3)
Small molecules: ATP, ROS (Reactive oxygen species); 4) Molecular complexes: Apoptosome,
C2 TNF, DISC FAS; 5) Molecular processes: MPT (Mitochondria permeabilization transition),
MOMP (Mitochondrial outer membrane permeabilization); 6) Phenotypes: Survival, Apoptosis,
NonACD (Non-apoptotic cell death). Below the table of logical rules defining the discrete mathe-
matical model is provided.
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The set of all possible states provides a discrete phase space of the system. The
state transition graph contains all possible ways of the systems dynamics (trajecto-
ries). In other words, it is the multidimensional epigenetic landscape of the cell fate
decision system. Note that the state transition graph is assumed to be rather sparse
compared to the fully connected graph where any two state transitions would be
possible. Hence, on this landscape, one can determine bifurcating states, points of
no return, etc.
The state transition graph allows to address the following question: Starting from
a distinguished state of a cell, what is the probability to arrive to each of the stable
states? In biological terms: Which proportions of a population of resting cells ex-
posed to death ligand will eventually display each of the different phenotypes - cell
fate?
To answer the question, we converted the state transition graph into a Markov
process of random walk on a graph, following the method described in [9]. To do
that, we associated to each transition between two states a probability (called tran-
sition probability). By applying classical algorithms to the transition probability
matrix (strongly connected decomposition and topological sort), we obtained an ab-
sorbing discrete Markov chain, and then analyzed it with classical techniques [10].
One of the critical points in such type of analysis lies in the choice of the transi-
tion probabilities. Once again, defining these probabilities directly from some em-
pirical observations is impossible at present time. Hence, these probabilities should
be derived from the logical model with the use of some additional assumptions.
The simplest assumption is to consider all transitions firing from a given state
as equiprobable. Biological interpretation of such an assumption is not simple. In
a way, we consider a “generic” cell in which all possible system trajectories take
place with equal probabilities (without dominance, i.e. any preferable route). One
can argue that in any particular concrete cell, this would not be true anymore and
that the generic cell is not representative of anything real observed in any biological
experiment. Having in mind this difficulty, we avoid direct interpretation of absolute
values of probabilities, concentrating rather on relative changes of them in response
to some system modifications such as removing a node or fixing a node’s activity. It
happens that such a “generic” cell model is already capable of reproducing a number
of known experimental facts.
When the state transition graph is parametrized by transition probabilities, one
can use standard techniques to compute the probability of hitting a given stable state,
considering that a random walk starts from a given initial state. Then this probabil-
ity is associated with a probability of observing a particular phenotype in given
experimental conditions. For doing this, it is convenient to define a unique initial
state, which we choose to represent the “physiological state”, the one representing
un-induced cells growing in a plate. In the model of Fig. 1 it is the state in which
all elements are inactive except ATP, FADD and cIAP. This is a stable state, which
looses its stability when TNF variable is changed from 0 to 1 and the dynamical
system starts to evolve in time.
Using this approach, we performed a series of in silico experiments in which the
probability of arriving to stable states was computed for the initial (”wild-type”)
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model, or for a series of modified (“mutant”) model. Typical model modifications
consisted in fixing some nodes’ activities to 0 or to 1. For our cell fate decision
model, the results are provided in Fig. 2. In [4] this table was systematically com-
pared with the experimental data of the cell death phenotype modifications observed
in various mutant experimental systems, including cell cultures and mice. The model
was able to qualitatively recapitulate all of them and to suggest some new yet un-
explored experimentally mutant phenotypes. The most interesting in this setting
would be to consider synthetic interactions between individual mutants, when sev-
eral nodes on the diagram are affected by a mutation simultaneously.
S
A
N
wild−type
S
A
N
antiox
0
S
N
APAF deletion
0
S
N
BAX deletion
0
S
BCL2 o.e.
S
N
CASP8 deletion
A
N
CASP8 active
A
N
cFlip deletion
A N
cIAP deletion
S A
N
FADD deletion
A N
NFkB deletion
S
NFkB o.e.
A
RIP1 deletion
S
A
N
XIAP deletion
S
N
z−VAD−fmk
0
RIP1 deletion
+ z−VAD−fmk
Fig. 2 Changes in the phenotype probabilities from the random walk on the state transition graph,
starting from the initial physiological state. Various “mutant” modifications of the dynamical sys-
tem are tested here. Here “A“ denotes Apoptosis, “N“ denotes Necrosis and “S“ denotes Survival,
“0” denotes Naive state. “O.e.” stands for overexpression of a protein, “antiox” corresponds to
blunting the capacity of NFκB to prevent ROS formation, “z-VAD fmk” simulates the effect of
caspase inhibitor z-VAD-fmk.
4 Identification of fragile points of the cell fate decision
machinery
Changing distribution of transition probabilities on the asynchronous state transition
graph can drastically change the probabilistic outcome of a computational experi-
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ment. At the same time, the probabilities for a random walk to converge to some
attractor depend also on the structure of the state transition graph which is deter-
mined solely from the discrete model. In order to understand what are the critical
determinants of a cellular choice, we applied a novel strategy of discrete model
analysis consisting in parametrizing the state transition graph by changing relative
importance of certain variables. In a certain sense, this strategy corresponds to a
sensitivity analysis, commonly applied for continuous models based on ordinary
differential equations and chemical kinetics approach [11].
First of all, we postulate that our “reference” parametrization corresponds to the
equal probabilities of any possible transition from a state. As mentioned earlier, this
corresponds to a “generic” cell model, where the relative speeds of all biochem-
ical processes are assumed equal. Mathematically, considering the dynamics as a
Markov process, all transitions from a given state x to any of its asynchronous suc-
cessor are assigned equal probabilities (if x has r successors, these probabilities are
equal to 1/r). We will modify this default parametrization by systematically chang-
ing relative speeds of certain elements. This will lead to some re-parametrization
of the state transition graph and consequent changes in the probabilities to reach
attractors.
The key idea of priority classes [12, 13] consists in grouping variables of a dis-
crete model into classes according to the speeds of the underlying processes govern-
ing their turnover rates. For instance, in the case of genetic regulatory networks, a
natural grouping consists in putting de novo protein synthesis (transcription + trans-
lation) in a slow transition class in comparison with other processes such as post-
translational protein modifications (phosphorylation, ubiquitination, ...) or complex
formation. Following this idea, we can regroup nodes into priority classes to which
some priority ratios w are assigned. Said differently, each variable xi is assigned a
priority value wi. For a given node, a value wi > 1 corresponds to a higher than de-
fault priority, and a value wi < 1 to a lower than default priority. The ratio wi can
be interpreted as a global turnover rate of the component represented by this node:
those that are produced (activated) and degraded (deactivated) fast will have a large
wi.
Consider a state x, with r asynchronous successors. By definition, between x and
each of its successors, one and only one variable can be updated. Let y denote one of
the successors of x, and i be the index of the corresponding updated variable. With
the uniform assumption described before, the probability of the transition (x → y)
is independent of i and is equal to 1/r. With priority classes, this probability is now
weighted by wi, making the transition more probable if component i belongs to a
“fast” class (wi greater than one) and less probable if it belongs to a “slow” class (wi
less than one). Obviously, for computing the actual transition probabilities px→y, a
normalization should be applied so that:
∑
y succ. of x
px→y = 1.
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Once the new values of the transition probabilities have been computed, the same
treatments as before can be applied, leading to new values for the probabilities to
reach the different phenotypes, starting from a given initial condition.
This general method may be applied in two different ways. First, one may use it
to compute more realistic probabilities, that could be compared to actual experimen-
tal results (the probability to reach an attractor being compared with the proportion
of cells exhibiting the corresponding phenotype). However, such calculations would
need a complete classification of the relative speeds of all biochemical mechanisms
involved in the model. Given the number and heterogeneity of these mechanisms, it
is still difficult to obtain such classification. Instead, we used the method as a sen-
sitivity analysis tool, in order to detect which variables are more critical than others
in the decision-making process. Using the reduced model evoked earlier (see [4]),
we considered each variable independently, and successively boosted it or slowed it
down by some multiplicative factor. More precisely, to detect the sensitivity of the
network with respect to the turnover of variable xi, we performed the calculations for
different values of wi, the other weights w j being kept at one (the reference value).
By comparing the probabilities to reach the three phenotypes -survival, apoptosis
and necrosis- with those of the initial model, one can detect whether the system’s
response is sensitive or not to the turnover rate of variable xi. We performed such
experiments for the nine inner variables of the reduced model. Figure 3 presents the
results we obtained.
 
Fig. 3 . Testing the effect of varying node turnovers on the resulting phenotypic probabilities.
The absciss on the graphs shows the value of w priority value, where w = 1 corresponds to the
probabilities computed for the default wild-type model (see Fig. 2). The colors are those adopted
in [4]: orange corresponds to apoptosis, purple to necrosis and green to survival.
The plots reveal several interesting properties. First, the most sensitive compo-
nents, which correspond to the curves with the highest amplitude, are RIP1, NFkB
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and CASP8. This reinforces the idea that these three components play a crucial role
in the decision process. This seems reasonable, especially for RIP1 and CASP8,
as they occupy an upstream position in the regulatory graph. Interestingly, CASP3
turnover does not seem to be so important, although CASP3 is a marker of apop-
tosis. This confirms that even though CASP3 is essential for the existence of apop-
tosis in the model (its removal completely suppress apoptotic outcome, see Fig. 2),
its turnover rate does not appear to be important in the dynamics of the decision
process (once it goes from 0 to 1, most of the decision has already been made).
Remarkably, the turnovers of MOMP and MPT, both contributing to the permeabi-
lization of mitochondrial membrane, have different effects: MOMP seems to affect
mainly the decision between survival and necrosis, while MPT plays a role in the
switch between apoptosis and necrosis.
The sensitivity analysis that is presented here is an extension of the results pro-
posed in [4]. In contrast with the all-or-none perturbations evoked in the previous
part (where a node is fixed to 0 or 1), here we consider finer perturbations by mod-
ifying the turnover rates of the model’s variables. A next step would be to consider
the relative strengths of the model’s interactions, instead of the model’s variables.
Such an approach is currently investigated.
5 Comparison with the fragilities exploited by cancer and its
treatment
Deregulations of the signalling pathways studied here can lead to drastic and serious
consequences. Hanahan and Weinberg proposed that escape of apoptosis, together
with other alterations of cellular physiology, represents a necessary event in can-
cer promotion and progression [1]. As a result, somatic mutations leading to im-
paired apoptosis are expected to be associated with cancer. In the cell fate model
presented here, most nodes can be classified as pro-apoptotic or anti-apoptotic ac-
cording to the results of “mutant” model simulations, which are correlated with
experimental results found in the literature. Genes classified as pro-apoptotic in
our model include caspases-8 and -3, APAF1 as part of the apoptosome complex,
cytochrome c (Cyt c), BAX, and SMAC. Anti-apoptotic genes encompass BCL2,
cIAP1/2, XIAP, cFLIP, and different genes involved in the NFkB pathway, includ-
ing NFKB1, RELA, IKBKG and IKBKB (not explicit in the model). Genetic alter-
ations leading to loss of activity of pro-apoptotic genes or to increased activity of
anti-apoptotic genes have been associated with various cancers. Thus, we can cross-
list the alterations of these genes deduced from the model with what is reported in
the literature and verify their role and implications in cancer.
For instance, concerning pro-apoptotic genes, frameshift mutations in the ORF
of the BAX gene are reported in > 50% of colorectal tumours of the micro-satellite
mutator phenotype [14]. Expression of CASP8 is reduced in≈24% of tumours from
patients with Ewing’s sarcoma [15]. Caspase-8 was suggested in several studies to
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function as a tumour suppressor in neuroblastomas [16] and in lung cancer [17] (see
Fig. 4).
On the other hand, constitutive activation of anti-apoptotic genes is often ob-
served in cancer cells. The most striking example is the over-expression of the
BCL2 oncogene in almost all follicular lymphomas, which can result from a t(14;18)
translocation that positions BCL2 in close proximity to enhancer elements of the im-
munoglobulin heavy-chain locus [18]. As for the survival pathway, elevated NFkB
activity, resulting from different genetic alterations or expression of the v-rel viral
NFkB isoform, is detected in multiple cancers, including lymphomas and breast can-
cers [19]. An amplification of the genomic region 11q22 that spans over the cIAP1
and cIAP2 genes is associated with lung cancers [20], cervical cancer resistance to
radiotherapy [21], and oesophageal squamous cell carcinomas [22] (see Fig. 4).
Some of the components of the cell fate decision machinery are considered cur-
rently for the use in cancer treatment in pre-clinical or clinical trials. To give some
examples, SMAC mimetics directly target dysregulated, neoplastic cells that over-
express IAPs or underexpress SMAC [23]. BCL-2 inhibitors, most notably BAX
mimetics, are currently passing clinical trials (for example, see [24]).
In our sensitivity analysis, the variables NFκB and CASP8 appear among the
most ”vulnerable” components of the cell fate decision machinery, which could ex-
plain why the gene products they represent are fragile points used by cancer.
BLC-2 does not show up as a much sensitive node in the model. However, its
direct target, MPT is a fragile site, accordingly to our analysis. Also analysis of our
model shows that RIP1 is a powerfull and sensitive switch able to reverse pheno-
type probabilities. Until so far we are not aware about possible targeting of RIP1
functions in cancer treatment, which can be explained by still relatively poor char-
acterization of its substrates and difficulties connected with targeting specific RIP1
activities.
6 Conclusion
Mathematical models provide a way to test biological hypotheses in silico. They re-
capitulate consistent heterogeneous published results and assemble disseminated in-
formation into a coherent picture using an appropriate mathematical formalism (dis-
crete, continuous, stochastic, hybrid, etc.), depending on the questions and the avail-
able data. Then, modeling consists of constantly challenging the obtained model
with available published data or experimental results (mutants or drug treatments,
in our case). After several refinement rounds, a model becomes particularly useful
when it can provide counter-intuitive insights or suggest novel promising experi-
ments.
Here, we have conceived a mathematical model of cell fate decision, based on
a logical formalization of well-characterized molecular interactions. Former mathe-
matical models only considered two cellular fates, apoptosis and cell survival [25].
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Fig. 4 Cell fate decision fragilities identified in various cancers. Flash arrows, hitting from left to
right, represent overexpression or amplification, those hitting from right to left show deletion and
down-regulation). Rectangular arrows point to components targeted by cancer treatment strategies
(SMAC and BAX mimetics).
In contrast, we include a non-apoptotic modality of cell death, mainly necrosis, in-
volving RIP1, ROS and mitochondria functions.
By analyzing properties of the state asynchronous transition graphs associated
with the discrete model, we implemented a procedure to simulate the process of
stochastic cellular decision making in response to activation of death receptors.
These simulations were able to predict relative changes for probabilities of cellu-
lar phenotypes in response to some system perturbations such as a knock-out of a
gene or treatment with a drug. These predictions happened to be fully compatible
with published data from mouse experiments, and provided new predictions to be
tested.
Moreover, on this model we have tested a novel strategy of discrete model analy-
sis, consisting in finding fragile or most sensitive places of the cell fate decision ma-
chinery. Changing the cellular parameters determining choices made at these fragile
sites affect the probabilities for a cell to reach a particular cellular phenotype. We
found out that this type of analysis can explain some of the common fragilities
associated with tumorigenesis and also with currently employed cancer treatment
strategies.
Acknowledgements We would like to acknowledge support by the APO-SYS EU FP7 project. A.
Zinovyev, S. Fourquet, L. Calzone and E. Barillot are members of the team “Systems Biology of
Cancer”, Equipe labellisee par la Ligue Nationale Contre le Cancer. L. Tournier is member of the
Systems Biology team in the laboratory MIG of INRA (french institute for agronomical research).
Cell death and life in cancer: mathematical modeling of cell fate decisions 13
The study was also funded by the Projet Incitatif Collaboratif “Bioinformatics and Biostatistics of
Cancer” at Institut Curie.
References
1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell
4;144(5):646-74.
2. McCormick F (2004) Cancer: survival pathways meet their end. Nature 18;428(6980):267-9.
3. Kroemer G. et al. (2008) Classification of cell death: recommendations of the Nomenclature
Committee on Cell Death 2009. Cell Death Differ 16(1):3-11.
4. Calzone L, Tournier L, Fourquet S, Thieffry D, Zhivotovsky B, Barillot E, Zinovyev A. (2010)
Mathematical modelling of cell-fate decision in response to death receptor engagement. PLoS
Comput Biol 5;6(3):e1000702.
5. Van Herreweghe F, Festjens N, Declercq W, Vandenabeele P. (2010) Tumor necrosis factor-
mediated cell death: to break or to burst, that’s the question. Cell Mol Life Sci 67(10):1567-
79.
6. Balazsi G, van Oudenaarden A, Collins JJ (2011) Cellular decision making and biological
noise: from microbes to mammals. Cell. 144(6):910-25.
7. Naldi A, Remy E, Thieffry D, Chaouiya C (2009) A reduction method for logical regula-
tory graphs preserving essential dynamical properties. Lecture Notes in Computer Science
5688:266280.
8. Chaouiya C, de Jong H, Thieffry D. (2006) Dynamical modeling of biological regulatory
networks. Biosystems 84(2):77-80.
9. Tournier L. and Chaves M. (2009) Uncovering operational interactions in genetic networks
using asynchronous boolean dynamics. Journal of Theoretical Biology 260(2):196-209.
10. Feller W (1968) An Introduction to Probability Theory and its Applications (Volume 1, Chap-
ter 3). Wiley.
11. Turanyi, T (1990). Sensitivity analysis of complex kinetic systems. Tools and applications.
Journal of Mathematical Chemistry 5:203248.
12. Faure´ A, Naldi A, Chaouiya C, Thieffry D (2006) Dynamical analysis of a generic boolean
model for the control of the mammalian cell cycle. Bioinformatics 22(14):e124e131.
13. Naldi A, Berenguier D, Faure A, Lopez F, Thieffry D, Chaouiya C. (2009) Logical modelling
of regulatory networks with GINsim 2.3. Biosystems 97(2):134-9.
14. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, et al. (1997) Somatic frameshift mu-
tations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science
275:967969.
15. Lissat A, Vraetz T, Tsokos M, Klein R, Braun M, et al. (2007) Interferon-gamma sensi-
tizes resistant Ewing’s sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-
induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity. Am J
Pathol 170:19171930.
16. Teitz T, Lahti JM, Kidd VJ (2001) Aggressive childhood neuroblastomas do not express
caspase-8: an important component of programmed cell death. J Mol Med 79:428436.
17. Shivapurkar N, Toyooka S, Eby MT, Huang CX, Sathyanarayana UG, et al. (2002) Differen-
tial inactivation of caspase-8 in lung cancers. Cancer Biol Ther 1:6569.
18. Croce CM (2008) Oncogenes and cancer. N Engl J Med 358:502511.
19. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to
major culprit. Nat Rev Cancer 2:301310.
20. Dai Z, Zhu WG, Morrison CD, Brena RM, Smiraglia DJ, et al. (2003) A comprehensive
search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and
cIAP2 as candidate oncogenes. Hum Mol Genet 12:791801.
14 Authors Suppressed Due to Excessive Length
21. Imoto I, Tsuda H, Hirasawa A, Miura M, Sakamoto M, et al. (2002) Expression of cIAP1, a
target for 11q22 amplification, correlates with resistance of cervical cancers to radiotherapy.
Cancer Res 62:48604866.
22. Imoto I, Yang ZQ, Pimkhaokham A, Tsuda H, Shimada Y, et al. (2001) Identification of
cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell
carcinomas. Cancer Res 61:66296634.
23. Chen DJ, Huerta S (2009) Smac mimetics as new cancer therapeutics. Anticancer Drugs
20(8):646-58.
24. Ready N, Karaseva NA, Orlov SV, Luft AV, Popovych O, Holmlund JT, Wood BA, Leopold
L (2011) Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic
Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer. J Thorac Oncol
6(4):781-785
25. Lavrik IN (2010) Systems biology of apoptosis signaling networks. Curr Opin Biotechnol
21(4):551-5.
